Description:

Founded in 2023, LEP Biomedical is a pharmaceutical controlled release company with a core mission to simplify and improve post-operative care for patients undergoing ophthalmic surgeries via the HyaGuard platform. HyaGuard is a proprietary controlled release platform created to specifically address the high failure (14-46%) and reoperation (2-27%) rates associated with bleb-forming glaucoma surgeries. HyaGuard is designed with both patient and surgeon in mind. It is lightweight, biodegradable, rapidly inserted under the conjunctiva in <30 sec and not externally visible. This simplifies surgeries while ensuring patient comfort and is aesthetically pleasing.